(1R,3R)-N<sup>1</sup>-[5-(1-Ethylpropyl)pyrazolo[1,5-a]pyrimidin-7-yl]-1,3-cyclopentanediamine
Castration-Resistant Prostate Carcinoma
Explore 215 assets in Castration-Resistant Prostate Carcinoma →Floatz Rating
C32/100
Confidence
Indicative
Sponsor
Nuvation Bio Inc.
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
17Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05191017CT.gov Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC | — | Withdrawn | — | — | — |
NCT04541225CT.gov Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Castration-Resistant Prostate Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| (1R,3R)-N<sup>1</sup>-[5-(1-Ethylpropyl)pyrazolo[1,5-a]pyrimidin-7-yl]-1,3-cyclopentanediamine (this asset) | Nuvation Bio Inc. | P1/2 | C · 32 |
| Darolutamide | Bayer | P4 | BBB |
| Enzalutamide | Prostate Cancer Clinical Trials Consortium | P4 | BBB |
| Prednisolone | Ding-Wei Ye | P4 | BBB |
| Mevrometostat | Prostate Cancer Clinical Trials Consortium | P3 | BB |
| Radium Ra-223 | University of California, San Francisco | P4 | BB |
| Cabozantinib | Rana McKay, MD | P3 | BB |
| Prednisone | Janssen Research & Development, LLC | P4 | BB |
| Abiraterone | AstraZeneca | P4 | BB |
+42 more in the Castration-Resistant Prostate Carcinoma cohort
Other indications for (1R,3R)-N<sup>1</sup>-[5-(1-Ethylpropyl)pyrazolo[1,5-a]pyrimidin-7-yl]-1,3-cyclopentanediamine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P1/2 | C · 32 |
| Breast Neoplasm | — | P1/2 | C · 32 |
| Prostate Carcinoma | — | P1/2 | C · 32 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. (1R,3R)-N<sup>1</sup>-[5-(1-Ethylpropyl)pyrazolo[1,5-a]pyrimidin-7-yl]-1,3-cyclopentanediamine in Castration-Resistant Prostate Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/1r3r-nsup1sup-5-1-ethylpropylpyrazolo15-apyrimidin-7-yl-13-cyclopentanediamine-castration-resistant-prostate-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →